Christoph Hoeller

Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer Receiving Immune Checkpoint Inhibitors.

Journal: European journal of clinical investigation

Published: March 27, 2026

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 19, 2026

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 19, 2026

Successful adjuvant nivolumab therapy in a toddler with xeroderma pigmentosum and stage III melanoma.

Journal: European journal of dermatology : EJD

Published: January 29, 2026

Corrigendum to "Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028": [ESMO Open 10 (2025) 104295].

Journal: ESMO open

Published: January 03, 2026

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Journal: Nature communications

Published: July 24, 2025

Management of Local Skin Reactions Caused by 5-FU 4% Cream for the Treatment of Actinic Keratosis: A Delphi Consensus.

Journal: Dermatology practical & conceptual

Published: March 18, 2025

Rare Lacrimal Gland Melanoma: A Case Report and Treatment Insights.

Journal: The American journal of case reports

Published: February 23, 2025

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 26, 2024

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 22, 2024

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 21, 2024

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 29, 2024

Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer Receiving Immune Checkpoint Inhibitors.

Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer Receiving Immune Checkpoint Inhibitors.

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

Successful adjuvant nivolumab therapy in a toddler with xeroderma pigmentosum and stage III melanoma.

Successful adjuvant nivolumab therapy in a toddler with xeroderma pigmentosum and stage III melanoma.

Corrigendum to "Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028": [ESMO Open 10 (2025) 104295].

Corrigendum to "Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028": [ESMO Open 10 (2025) 104295].

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Management of Local Skin Reactions Caused by 5-FU 4% Cream for the Treatment of Actinic Keratosis: A Delphi Consensus.

Management of Local Skin Reactions Caused by 5-FU 4% Cream for the Treatment of Actinic Keratosis: A Delphi Consensus.

Rare Lacrimal Gland Melanoma: A Case Report and Treatment Insights.

Rare Lacrimal Gland Melanoma: A Case Report and Treatment Insights.

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024.

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024.

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.